$5.23
4.18% today
Nasdaq, Feb 05, 04:20 pm CET
ISIN
US30068X1037
Symbol
XGN

Exagen Inc Stock price

$5.02
+1.63 48.08% 1M
+2.62 109.17% 6M
+0.92 22.44% YTD
+2.98 146.08% 1Y
-3.75 42.76% 3Y
-15.41 75.43% 5Y
-13.56 72.98% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+1.14 29.38%
ISIN
US30068X1037
Symbol
XGN
Sector

Key metrics

Market capitalization $88.54m
Enterprise Value $90.05m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.62
P/S ratio (TTM) P/S ratio 1.59
P/B ratio (TTM) P/B ratio 6.84
Revenue growth (TTM) Revenue growth 8.00%
Revenue (TTM) Revenue $55.75m
EBIT (operating result TTM) EBIT $-15.40m
Free Cash Flow (TTM) Free Cash Flow $-5.77m
Cash position $22.04m
EPS (TTM) EPS $-0.94
P/E forward negative
P/S forward 1.59
EV/Sales forward 1.62
Short interest 0.45%
Show more

Is Exagen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Exagen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Exagen Inc forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Exagen Inc forecast:

Buy
83%
Hold
17%

Financial data from Exagen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
56 56
8% 8%
100%
- Direct Costs 23 23
3% 3%
41%
33 33
18% 18%
59%
- Selling and Administrative Expenses 42 42
9% 9%
75%
- Research and Development Expense 4.80 4.80
26% 26%
9%
-14 -14
44% 44%
-24%
- Depreciation and Amortization 1.82 1.82
26% 26%
3%
EBIT (Operating Income) EBIT -15 -15
42% 42%
-28%
Net Profit -17 -17
48% 48%
-30%

In millions USD.

Don't miss a Thing! We will send you all news about Exagen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exagen Inc Stock News

Neutral
GlobeNewsWire
about 19 hours ago
CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
24 days ago
New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn CARLSBAD, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced it has received conditional approval from ...
Neutral
GlobeNewsWire
about 2 months ago
The milestone demonstrates AVISE CTD's value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care The milestone demonstrates AVISE CTD's value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care
More Exagen Inc News

Company Profile

Exagen, Inc. is a commercial-stage diagnostics company. It engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company operates under the Avise brand. Exagen was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Head office United States
CEO John Aballi
Employees 179
Founded 2002
Website www.exagen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today